University of South Australia research has shown promising results into Medlab’s key technology to improve delivery of medicines for greater effectiveness.

Australian biotech Medlab Clinical (ASX:MDC), which specialises in nano-particle delivery technology to enhance medicinal effectiveness, has announced promising results from research into its NanoCelle NanaBis program.

Researchers from the School of Pharmacy and Medical Sciences at University of South Australia have independently confirmed that NanaBis has two times more bioavailability than an Australian Register of Therapeutic Goods (ART) approved oral cannabis (CBD and THC) medicine.

Bioavailability is the proportion of a drug or other substance which enters the circulation when introduced into the body so as to have an active effect.

The research was conducted using a Population pharmacokinetics (PopPK) study, which examines variability in drug concentrations within a patient population receiving clinically relevant doses of a drug of interest.

PopPK methods use mathematical models to describe PK data and draw conclusions. Bioavailability is a key indicator of drug absorption and refers to the extent and rate at which the active moiety (drug or metabolite) is absorbed from a drug product and successfully enters systemic circulation, thereby accessing the site of action.


About NanoCelle NanaBis program

NanaBis is scientifically optimised to use a 1 to 1 ratio of THC and CBD and is enhanced by Medlab’s nano-particle drug delivery technology NanoCelle for intra-oral (buccal) spray formulations.

The NanoCelle delivery platform is a patented chemical construct that uses US Food and Drug Administration (FDA) approved compounds for the creation of standardised nanoparticles.

Studies into NanoCelle have shown it provides quicker onset and superior bioavailability than tablets, sublingual emulsions, and liposomes at equivalent doses.

NanaBis met both primary and secondary endpoints in the advanced cancer pain trial at Royal North Shore Hospital and has now received Australian and UK ethics approvals for Phase 3 trials.

Medlab signed a trade deal with UK’s Cultech Limited for its NRGBiotic for patients with a major depressive disorder. Cultech is the former contract manufacturer of its patented probiotic.

The company has also signed a key Southeast Asian distribution deal, opening another target market up to its nutraceutical brands.


Central to Medlab’s drug development programs

Medlab uses NanoCelle in all its primary  and secondary drug development programs.

Primary drug development includes its trademarked NanaBis cannabinoids with FDA recognised API Drug Master Files (DMFs) for the treatment of cancer bone pain (Bone METs).

The company has plans to extend its usage to benefit patients with other larger neuropathic pain.

NanoCelle is used in Medlab’s secondary drug development programs including:

  • Trademarked NANOCBD – cannabinoid  (CBD)  with a  FDA  recognised  API  DMF  for  occupational stress with plans for mild, chronic pain management
  • MDC2000, proposed  FDA  505(b)(2)  program  using  an  earlier,  approved  drug  substance  for depression to treat major depressive disorders
  • NASAL RNA, Nucleic Acid collaboration with Woolcock Institute at Macquarie University and University of  New  South  Currently  in  pre-clinical  stages  for  a  nasal  vaccine  delivery  using nucleic acid for new vaccine and/or anti-viral technologies.


This article was developed in collaboration with Medlab Clinical, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.